SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 6 — Preventive Visit — Judy Garland

PatientJudy Garland
Date of birth1993-06-10
IdentifiersMRN HR-ML005-SYN; SSN (made up) 000-05-6127
Document date2026-09-28
AuthorMargaret Ellsworth-Diaz, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Periodic adult preventive visit. [S]

History of Present Illness

Ms. Garland is a 33-year-old singer and actor with a barbiturate use disorder on a phenobarbital taper, a mild stimulant use disorder in early remission, chronic insomnia, and depression with anxiety on sertraline, who comes for her yearly preventive visit four weeks after her ten-week review and six months after the birth of her third child. She has followed the written taper schedule: the step two weeks ago went smoothly, and today is her next planned step, to 40.5 mg a day. She has taken no secobarbital, dextroamphetamine, or any other sedative or stimulant. She sleeps about six hours on most nights with her CBT-I routine and a fixed wake time, even after late rehearsals. Her mood and worry are better, and her PHQ-9 today is 7. She eats three meals on most days. She is due for her second contraceptive injection. She still smokes about ten cigarettes a day. [S]

ElementDetail
VisitPeriodic adult preventive visit, age 33
Phenobarbital48.6 mg a day; step to 40.5 mg a day today per the written schedule
Other sedatives or stimulantsNone
SleepAbout six hours on most nights
MoodPHQ-9 7; item 9 scored 0
MedicinesPhenobarbital 16.2 mg tablets on the taper schedule; sertraline 50 mg daily; medroxyprogesterone injection every 13 weeks

Health risk assessment. Completed by the patient on a tablet in the waiting room and reviewed with her by Dr. Ellsworth-Diaz. [S]

DomainFinding
Self-rated healthGood, and better than in the summer
PsychosocialBusy with work and three children, with help at home; weekly psychotherapy; a close friend she confides in
Substance usePrescribed phenobarbital on a taper only; no other sedatives or stimulants; a glass of wine a week before the taper and none since
TobaccoAbout ten cigarettes a day
Physical activityRehearsals and dance practice most days; walks on days off
NutritionThree meals on most days and snacks around rehearsals
SleepAbout six hours on most nights
Sexual and reproductive healthNot planning a pregnancy; on injectable contraception
Safety at homeFeels safe at home; no one hurts or threatens her
Road safetyWears a seat belt; does not drive after evening doses
Activities of daily livingIndependent
Oral healthDental visit in the past year

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever or night sweats; weight up gradually, which she is comfortable with
EyesNegativeNo vision change
Ears, nose, mouth, and throatNegativeVoice fully recovered since the laryngitis
CardiovascularNegativeNo chest pain or palpitations
RespiratoryNegativeNo cough or breathlessness
GastrointestinalNegativeNo abdominal pain or change in bowel habit
GenitourinaryNegativeIrregular light spotting on the injection; no pelvic pain
MusculoskeletalNegativeNo joint pain
IntegumentaryNegativeNo rash
NeurologicalNegativeNo tremor, unsteadiness, or seizure-like episodes
PsychiatricNegativeMood better; PHQ-9 7; no thoughts of suicide or self-harm; no cravings for secobarbital

11 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicineTwo capsules at bedtime; no extra dosesOral route2026-06-22 to 2026-07-06completedS
Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energyOne tablet each morningOral route2026-06-22 to 2026-07-20completedS
Dextroamphetamine 5 mg oral tablet, one tablet each morning for two weeks, then stopOne tablet each morning for two weeks, then stopOral route2026-07-20 to 2026-08-03completedS
Sertraline 25 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-22 to 2026-06-29completedS
Sertraline 50 mg oral tablet, one tablet dailyOne tablet dailyOral route2026-06-29activeS
Phenobarbital 32.4 mg oral tablet, one tablet three times daily (97.2 mg a day), started in hospital in place of secobarbitalOne tablet three times dailyOral route2026-07-06 to 2026-07-20completedS
Phenobarbital 16.2 mg oral tablet on a written taper schedule in two or three divided doses: 81 mg a day from the four-week visit, lowered by 8.1 to 16.2 mg about every two weeks and paused when needed; dispensed two weeks at a timePer the written taper schedule, in two or three divided dosesOral route2026-07-20activeS
Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks150 mg intramuscularly every 13 weeksIntramuscular route2026-06-22activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for throat pain, no more than 3,000 mg a day, for up to five daysTwo tablets every 6 hours as needed, up to 3,000 mg a dayOral route2026-08-17 to 2026-08-22completedS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
2026-09-28Body height151cmS
2026-09-28Body weight49.4kgS
2026-09-28Body mass index (BMI) [Ratio]21.7kg/m2S
2026-09-28Systolic blood pressure110mm[Hg]S
2026-09-28Diastolic blood pressure70mm[Hg]S
2026-09-28Heart rate70/minS
2026-09-28Respiratory rate14/minS
2026-09-28Body temperature36.6CelS
2026-09-28Oxygen saturation in Arterial blood by Pulse oximetry99%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
2026-09-28Patient Health Questionnaire 9 item (PHQ-9) total score [Reported]7{score}S

Physical Exam

Vital signs recorded on 2026-09-28; see the Vital Signs section. [S]

SystemFinding
ConstitutionalWell; weight 49.4 kg, BMI 21.7; blood pressure 110/70; pulse 70
EyesNo nystagmus
NeckNo thyroid enlargement or nodes
CardiovascularRegular rhythm; no murmur
RespiratoryClear to auscultation bilaterally
AbdomenSoft and non-tender
SkinNo rash
NeurologicalNo tremor; gait and finger-to-nose testing normal
PsychiatricBright and engaged; no signs of sedation or withdrawal

Problems

ProblemClinical statusVerificationCodeProvenance
Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pillsactiveconfirmed F13.20S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis.
Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pillsactiveconfirmed F15.10S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription.
Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescenceactiveconfirmed G47.00S — Synthetic modern diagnosis anchored to the documented sleeping pills.
Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implantsactiveconfirmed Z30.013S — Synthetic contraception need; the birth is documented.
Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomaniaactiveconfirmed F32.1S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used.
Acute laryngitis, probably viral, during rehearsals, treated with voice rest and supportive care; resolvedresolvedconfirmed J04.0S — Synthetic acute illness; not a historical claim.

Assessment and Plan

Personalized prevention plan. A written copy was given to the patient. [S]

ServiceStatusDetail
Blood pressure screeningCompleted today110/70 mmHg
Cervical cancer screeningUp to dateNormal cervical cytology with HPV testing during prenatal care last year; next in five years
HIV screeningOrderedOnce for all adults; drawn today with her agreement
Hepatitis C screeningOrderedOnce for all adults; drawn today
Hepatitis B screeningOrderedTriple panel once for all adults; drawn today
Chlamydia and gonorrhea screeningNot indicatedAge over 24 with one long-term partner and no new risk
Intimate partner violence screeningCompleted todayNegative; she feels safe at home
Depression screeningCompleted todayPHQ-9 7, from 14 at intake; item 9 scored 0; in treatment
Unhealthy alcohol and drug useUp to dateAUDIT-C 2 and DAST-10 6 at intake; in treatment; no alcohol during the taper
Tobacco cessationDeclinedAbout ten cigarettes a day; nicotine replacement and counseling offered; she would like to finish the taper first and will be asked again at the next visit
ContraceptionCompleted todaySecond medroxyprogesterone injection; phenobarbital does not weaken it
Diabetes and cholesterol screeningNot indicatedDiabetes screening begins at 35 for adults with overweight; statin assessment begins at 40
Breast and colorectal cancer screeningNot indicatedBegin at 40 and 45
Influenza vaccine, this seasonCompleted todayGiven today
COVID-19 vaccine, this seasonDeclinedDiscussed; she will decide at the next visit
Tetanus, diphtheria, and pertussisUp to dateTdap at intake
HPV vaccineDeclinedShared decision-making for adults 27 to 45; she chose not to have it

Immunizations given today: Influenza vaccine, inactivated, this season [S]

Guideline basis: Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits (2025); VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024); CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026); Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026); USPSTF A and B Recommendations (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Four-month review in four weeks with blood count, ferritin, metabolic panel and liver tests. HIV, hepatitis C and hepatitis B results by phone. Next contraceptive injection in 13 weeks. Next preventive visit in one year. Next scheduled visit 2026-10-26: four-month review: phenobarbital taper, sleep, mood, laboratory checks and the plan to finish. [S]

Advance Care Planning

Voluntary advance care planning discussion of about 17 minutes, with her consent. She named a health care agent, and a health care proxy form was completed; the agent is recorded in the chart and is not named here. She said that what matters most to her is her children, her work, and being treated as a person rather than a problem. She asked that, if she were ever too ill to speak for herself, her treatment for the pills be continued without blame. She chose not to record specific treatment preferences today. The plan will be revisited yearly or after any serious illness. [S]